Abstract: Decitabine (5-aza-2'-deoxycytidine) is a potent DNA hypomethylating agent (HMA) widely utilized in the treatment of myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). While traditionally recognized for its direct cytotoxic and epigenetic gene-reactivating properties, recent research has illuminated its profound immunomodulatory effects, establishing a strong rationale for its use in epigenetic priming alongside immunotherapy. Decitabine induces "viral mimicry" through the activation of endogenous retroviruses, upregulates tumor-associated antigens and MHC class I molecules, and modulates various immune effector cells. However, its clinical efficacy is often limited by rapid metabolic degradation, primary and secondary resistance, and the paradoxical upregulation of immune checkpoint molecules such as PD-1 and PD-L1. This review synthesizes current literature on the pharmacological activity, molecular mechanisms, and structure-activity relationships of decitabine. Furthermore, it explores current limitations and future perspectives, particularly focusing on novel oral formulations (e.g., decitabine/cedazuridine) and synergistic combination strategies with immune checkpoint inhibitors and targeted therapies like venetoclax to overcome resistance and improve patient outcomes.
1. Introduction
Aberrant DNA methylation at CpG islands within promoter regions is a hallmark of cancer, leading to the epigenetic silencing of critical tumor suppressor genes involved in cell cycle regulation, differentiation, and apoptosis [1]. In myeloid neoplasms such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), mutations affecting DNA methylation machinery (e.g., DNMT3A, TET2) are early events in malignant transformation [3][6]. To counteract these epigenetic aberrations, hypomethylating agents (HMAs) like decitabine (5-aza-2'-deoxycytidine) and azacitidine were developed and have become the cornerstone of therapy for patients with higher-risk MDS and older or unfit patients with AML [1][4][7].
Beyond their direct cytotoxic and differentiating effects on leukemic blasts, HMAs are now recognized for their profound impact on the tumor microenvironment and the host immune system. The concept of "epigenetic priming" has emerged, wherein decitabine is used to alter the epigenetic landscape of tumor cells, thereby enhancing their immunogenicity and sensitizing them to subsequent or concurrent immunotherapies [1][3]. This review explores the intersection of decitabine's epigenetic mechanisms and immunotherapy, detailing its pharmacological profile, structural properties, current clinical limitations, and future therapeutic directions.
2. Pharmacological Activity
Decitabine exhibits potent antineoplastic and immunomodulatory activities. Clinically, it is typically administered intravenously, with the 5-day regimen (20 mg/m2 daily) being a standard approach for MDS and AML, though extended 10-day schedules have shown high response rates, particularly in patients with TP53 mutations [1][4]. The drug's primary pharmacodynamic effect is the induction of global DNA hypomethylation, which can be quantified using surrogate markers such as long interspersed nuclear element-1 (LINE-1) demethylation [5].
In the context of immunomodulation, decitabine exerts diverse effects on various immune cell populations. It has been shown to augment natural killer (NK) cell responsiveness and enhance antibody-dependent cellular cytotoxicity (ADCC) against AML blasts, such as when combined with anti-CD33 monoclonal antibodies [1]. Furthermore, decitabine suppresses myeloid-derived suppressor cells (MDSCs), thereby disrupting tumor-induced immune tolerance [1]. Interestingly, decitabine also promotes the expansion and stability of regulatory T cells (Tregs) through the demethylation of the FOXP3 promoter. While this Treg induction can be harnessed therapeutically in autoimmune diseases and to mitigate graft-versus-host disease (GvHD) following allogeneic stem cell transplantation, it represents a complex variable in the context of anti-tumor immunity [1][2].
3. Molecular Mechanism of Action
Decitabine is an S-phase-specific agent that must be incorporated into DNA during cellular replication to exert its effects [1][5]. Once incorporated into the DNA strand as 5-aza-2'-deoxycytidine-triphosphate (5-aza-dCTP), it is recognized by DNA methyltransferase 1 (DNMT1). Instead of methylating the cytosine ring, DNMT1 becomes irreversibly and covalently bound to the decitabine residue. This covalent trapping leads to the proteasomal degradation and depletion of DNMT1, resulting in passive DNA hypomethylation during subsequent cell divisions and the reactivation of aberrantly silenced genes [1][5].
The mechanism underlying epigenetic priming for immunotherapy involves several distinct pathways. First, decitabine induces "viral mimicry" by demethylating and activating endogenous retroviruses (ERVs) and other transposable elements. The transcription of these elements forms double-stranded RNA (dsRNA), which triggers an innate immune interferon response [1][4]. Second, DNA demethylation upregulates the expression of major histocompatibility complex class I (MHC-I), co-stimulatory molecules (e.g., CD80, CD86), and cancer testis antigens (e.g., NY-ESO-1, MAGE-A) on the surface of malignant cells, thereby potentiating tumor-specific cytotoxic T lymphocyte (CTL) responses [1][3].
4. Structure-Activity Relationship (SAR)
Decitabine is a synthetic analog of the naturally occurring nucleoside deoxycytidine, characterized by the substitution of a nitrogen atom for a carbon atom at the 5-position of the cytosine ring [1]. Unlike its counterpart azacitidine (5-azacytidine), which possesses a 2'-hydroxyl group and incorporates predominantly (80-90%) into RNA, decitabine lacks this hydroxyl group and is incorporated exclusively into DNA [1].
The intracellular activation of decitabine requires sequential phosphorylation, with the initial and rate-limiting step catalyzed by the enzyme deoxycytidine kinase (DCK) [1]. A critical structural vulnerability of decitabine is its susceptibility to rapid deamination and inactivation by cytidine deaminase (CDA), an enzyme highly expressed in the gastrointestinal tract and liver. This rapid degradation severely limits the oral bioavailability of decitabine and results in a short plasma half-life (approximately 35-40 minutes in vivo) [1][5].
To overcome this structural limitation, next-generation molecules have been developed. Guadecitabine (SGI-110) is a dinucleotide composed of decitabine linked to deoxyguanosine. This structural modification renders the molecule resistant to CDA degradation, allowing for a prolonged half-life and extended exposure of the active decitabine metabolite following subcutaneous administration [1][3].
5. Current Limitations
Despite its clinical utility, decitabine therapy faces several significant limitations:
Drug Resistance: Both primary and secondary resistance to HMAs are nearly inevitable. Tumor-intrinsic resistance mechanisms include a high ratio of CDA to DCK (leading to increased drug inactivation and decreased activation), loss of DCK expression, and the persistence or expansion of resistant leukemic subclones [1]. Furthermore, decitabine monotherapy fails to completely eradicate quiescent leukemic stem cells, making disease relapse a persistent challenge [1][4].
Immune Evasion: A paradoxical effect of decitabine's demethylating activity is the upregulation of inhibitory immune checkpoint molecules. Decitabine induces the demethylation of the PD-1 promoter, leading to increased expression of PD-1, PD-L1, PD-L2, and CTLA-4 on T cells and tumor cells. This upregulation blunts the anti-tumor immune response and is strongly associated with secondary resistance to HMA therapy [1][3][6].
Pharmacokinetics and Toxicity: The rapid degradation of decitabine by CDA necessitates frequent parenteral administration, placing a significant burden on patients [5]. Additionally, decitabine is highly myelosuppressive, frequently causing severe neutropenia and thrombocytopenia, which increases the risk of life-threatening opportunistic infections [4][5].
6. Future Perspectives
To address the limitations of decitabine monotherapy, several innovative strategies are currently shaping the future of myeloid leukemia and MDS treatment:
Combination with Immune Checkpoint Inhibitors (ICIs): Because decitabine upregulates PD-1 and PD-L1, there is a strong biological rationale for combining HMAs with ICIs (e.g., nivolumab, pembrolizumab, durvalumab, or ipilimumab). This combination aims to overcome HMA-induced immune evasion and harness the epigenetic priming effect (increased tumor antigens and viral mimicry) to generate a synergistic, durable anti-leukemic T-cell response. Early-phase clinical trials have shown promising overall response rates and manageable safety profiles for these combinations [1][3][6].
Oral Formulations: The recent FDA approval of ASTX727 (Inqovi), a fixed-dose oral combination of decitabine (35 mg) and the novel CDA inhibitor cedazuridine (100 mg), represents a major advancement. Cedazuridine prevents the breakdown of decitabine in the gut and liver, achieving systemic exposure and DNA demethylation equivalent to intravenous decitabine. This oral formulation significantly improves patient convenience and facilitates long-term epigenetic maintenance therapy [1][3][5][7].
Targeted Therapy Combinations: Combining decitabine with the BCL-2 inhibitor venetoclax has revolutionized the treatment of older and unfit AML patients. While decitabine alone cannot eradicate leukemic stem cells, the addition of venetoclax selectively targets these cells by disrupting oxidative phosphorylation. This combination yields high complete remission rates and prolonged survival, establishing a new standard of care [1][3][8]. Future trials are also exploring triplet combinations, adding targeted agents like FLT3 or IDH inhibitors to the decitabine/venetoclax backbone [1][7].
